Agomelatine and hepatotoxicity: Implications of cumulated data derived from spontaneous reports of adverse drug reactions

Pharmacopsychiatry

Volumn 46, Issue 6, 2013, Pages 214-220

  Gahr, M ^a   Freudenmann, R W ^a   Connemann, B J ^a,b   Hiemke, C ^b   Schonfeldt Lecuona C ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

adverse drug reactions; antidepressants; hepatopathy; liver enzymes; melatonin; pharmacovigilance

Indexed keywords

AGOMELATINE;

ADULT; ADVERSE OUTCOME; ARTICLE; ASYMPTOMATIC DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL FEATURE; COMORBIDITY; FEMALE; HUMAN; LIVER TOXICITY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; TREATMENT DURATION;

ACETAMIDES; ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; DATABASES, FACTUAL; DRUG-INDUCED LIVER INJURY; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84884287231     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0033-1353156     Document Type: Article

References (49)

1. EMA Agomelatine. Summary of product characteristics. EMA: 2009
2. Kennedy S., Eisfeld B. Agomelatine and its therapeutic potential in the depressed patient. Neuropsychiatric Dis Treat: 2007; 3 423 428
3. Lerner A., Case J., Takahashi Y. et al. Isolation of melatonin, the pineal factor that lightens melanocytes. J Am Chem Soc: 1958; 80 2587
4. Nordlund J., Lerner A. The effects of oral melatonin on skin color and on the release of pituitary hormones. J Clin Endocrinol Metabol: 1977; 45 768 774
5. Brzezinski A., Vangel M., Wurtman R. et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev: 2005; 9 41 50
6. Popoli M. Agomelatine: innovative pharmacological approach in depression. CNS Drugs: 2009; 23 (Suppl.2) 27 34
7. Fornaro M., Prestia D., Colicchio S. et al. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropsychopharmacol: 2010; 8 287 304
8. Masson-Pévet M., Recio J., Guerrero H. et al. Effects of two melatonin analogues, s-20098 and s-20928, on melatonin receptors in the pars tuberalis of the rat. J Pin Res: 1998; 25 172 176
9. San L., Arranz B. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur Psychiatry: 2008; 23 396 402
10. Wehr T. Photoperiodism in humans and other primates: Evidence and implications. J Biol Rhythms: 2001; 16 348 364
11. 2B receptor profile in the rat central nervous system. Neuroscience: 1997; 76 323 329
12. Millan M., Gobert A., Lejeune F. et al. The novel melatonin agonist agomelatine (S20098) is an antangonist at 5-hydroxytryptamine 2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther: 2003; 306 954 964
13. Millan M., Marin P., Kamal M. et al. The melatonergic agonist and clinically active antidepressant, agomelatine, is a neutral antagonist at 5-HT2C receptors. Int J Neuropsychopharmacol: 2010; 14 768 783
14. Rosen R., Lane R., Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol: 1999; 19 67 85
15. Landolt H., Meier V., Burgess H. et al. Serotonin-2-receptors and human sleep: effects of a selective antagonist on EEG power spectra. Neuropsychopharmacology: 1999; 21 455 466
16. Landolt H., Wehrle R. Antagonism of serotonergic 5-HT2A/2C receptors: Mutual improvement of sleep, cognition, and mood? Eur J Neurosci. 2009; 29 1795 1809
17. Stahl S. Novel mechanisms of antidepressant action: norepinehprine and dopamine disinhibition (NDDI) plus melatonergic agonism. Int J Neuropsychopharmacol: 2007; 10 575 578
18. EMA CMHP assessment report for valdoxan. London: 2008
19. Kasper S., Hamon M. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action. World J Biol Psychiatry: 2009; 10 117 126
20. Singh S., Singh V., Nilamadhab K. Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal. Int J Neuropsychopharmacol: 2012; 15 417 428
21. Froböse T., Slawik H., Schreiner R. et al. Agomelatine improves sleep in a patient with fatal familial insomnia. Pharmacopsychiatry: 2012; 45 34 36
22. Zajecka J., Schatzberg A., Stahl S. et al. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol: 2010; 30 135 144
23. Loo H., Hale A., D'Haenen H. Determination of the dose of agomelatine, a melatonergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol: 2002; 17 239 247
24. Kennedy S., Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol: 2006; 16 223 244
25. 2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Psychopharmacol: 2007; 10 661 673
26. Stahl S., Fava M., Trivedi M. et al. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry: 2010; 71 616 626
27. Hale A., Corral R-M, Menacci C. et al. Superior antidepressant efficacy results of agomelatine vs. fluoxetine in severe MDD patients: a randomized, double-blind study. Int Clin Psychopharmacol: 2010; 25 305 314
28. Lemoine P., Guilleminault C., Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry: 2007; 68 1723 1732
29. Kasper S., Hajak G., Wulff K. et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry: 2010; 71 109 120
30. Kennedy S., Rivzi S., Fulton K. et al. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol: 2008; 28 329 333
31. DeBerardis D., Di Iorio G., Acciavatti T. et al. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine. CNS Neurolog Dis Drug Targ: 2011; 10 119 132
32. Montgomery S., Kennedy S., Burrows G. et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol: 2004; 19 271 280
33. Loo H., Daléry J., Macher J. et al. Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin-agonist and selective 5HT2c receptors antagonist, in the treatment of major depressive disorders. L'Encephale: 2003; 29 165 171
34. Imboden C., Hatzinger M. Agomelatine-induced akathisia with concomitant duloxetine medication: a case report. Pharmacopsychiatry: 2012; 45 162 163
35. Vuppalanchi R., Hayashi P., Chalasani N. et al. Drug-Induced Liver Injury Network (DILIN). Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury network. Aliment Pharmacol Ther: 2010; 32 1174 1183
36. Nelson S., Mitchell J., Snodgrass W. et al. Hepatotoxicity and metabolism of iproniazid and isopropylhydrazine. J Pharmacol Exp Ther: 1978; 206 574 585
37. Tabak F., Gunduz F., Tahan V. et al. Sertraline hepatotoxicity: report of a case and review of the literature. Dig Dis Sci: 2009; 54 1589 1591
38. Collados V., Hallal H., Andrade R. Sertraline hepatotoxicity: report of a case and review of the literature. Dig Dis Sci: 2010; 55 1806 1807
39. Yildirim B., Tuncer C., Ergun M. et al. Venlafaxine-induced hepatotoxicity in a patient with ulcerative colitis. Ann Hepatol: 2009; 8 271 272
40. Larrey D., Rueff B., Pessayre D. et al. Cross hepatotoxicity between tricyclic antidepressants. Gut: 1986; 27 726 727
41. Stuhec M. Agomelatine-induced hepatotoxicity. Wien Klin Wochenschr: 2013; 125 225 226
42. Laux G., Group V. S. The antidepressant agomelatine in daily practice: results of the non-interventional study VIVALDI. Pharmacopsychiatry: 2012; 45 284 291
43. Howland R. Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disorder. Neuropsychiatric Dis Treat: 2009; 5 563 576
44. Marchesini G., Bugianesi E., Forlani G. et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology: 2003; 37 917 923
45. Canbay A., Chen S., Gieseler R. et al. Overweight patients are more susceptible for acute liver failure. Hepatogastroenterology: 2005; 52 1516 1520
46. Schwabe U., Paffrath D. Arzneiverordnungsreport 2011. In: Berlin, Heidelberg Springer: 2011
47. Howland R. Publication bias and outcome reporting bias: agomelatine as a case example. J Psychosoc Nurs Ment Health Serv: 2011; 49 11 14
48. Howland R. A benefit-risk assessment of agomelatine in the treatment of major depression. Drug Saf: 2011; 34 709 731
49. Jacob D., Marrón B., Ehrlich J. et al. Pharmacovigilance as a tool for safety and monitoring: a review of general issues and the specific challenges with end-stage renal failure. Drug Healthc Patient Saf: 2013; 5 105 112